Ligand Pharmaceuticals (LGND) Expected to Announce Earnings on Thursday

Ligand Pharmaceuticals (NASDAQ:LGND) is anticipated to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Ligand Pharmaceuticals to post earnings of $1.96 per share and revenue of $58.7070 million for the quarter. Ligand Pharmaceuticals has set its FY 2025 guidance at 6.700-7.000 EPS.Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

Ligand Pharmaceuticals (NASDAQ:LGND) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The company had revenue of $47.63 million during the quarter, compared to analysts’ expectations of $43.87 million. Ligand Pharmaceuticals had a negative return on equity of 9.21% and a negative net margin of 40.44%.Ligand Pharmaceuticals’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.40 earnings per share. On average, analysts expect Ligand Pharmaceuticals to post $2 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Ligand Pharmaceuticals Stock Performance

Shares of NASDAQ:LGND opened at $191.24 on Tuesday. The stock’s 50-day simple moving average is $174.98 and its two-hundred day simple moving average is $139.55. The stock has a market capitalization of $3.75 billion, a price-to-earnings ratio of -47.81 and a beta of 0.95. Ligand Pharmaceuticals has a 52-week low of $93.58 and a 52-week high of $194.44.

Insiders Place Their Bets

In related news, Director Jason Aryeh sold 10,000 shares of the stock in a transaction dated Tuesday, September 23rd. The stock was sold at an average price of $170.81, for a total transaction of $1,708,100.00. Following the completion of the sale, the director owned 69,289 shares in the company, valued at approximately $11,835,254.09. This trade represents a 12.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director John W. Kozarich sold 467 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $179.44, for a total value of $83,798.48. Following the sale, the director directly owned 45,055 shares in the company, valued at $8,084,669.20. This trade represents a 1.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 10,934 shares of company stock valued at $1,867,674 in the last quarter. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Ligand Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in LGND. Captrust Financial Advisors boosted its position in shares of Ligand Pharmaceuticals by 31.8% during the second quarter. Captrust Financial Advisors now owns 15,609 shares of the biotechnology company’s stock worth $1,774,000 after acquiring an additional 3,767 shares during the last quarter. Scott Marsh Financial LLC purchased a new stake in Ligand Pharmaceuticals in the 2nd quarter worth $802,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Ligand Pharmaceuticals by 2.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,021 shares of the biotechnology company’s stock valued at $1,139,000 after purchasing an additional 252 shares during the last quarter. Qube Research & Technologies Ltd grew its position in shares of Ligand Pharmaceuticals by 258.1% during the second quarter. Qube Research & Technologies Ltd now owns 18,085 shares of the biotechnology company’s stock valued at $2,056,000 after purchasing an additional 13,035 shares in the last quarter. Finally, Baird Financial Group Inc. grew its position in shares of Ligand Pharmaceuticals by 12.5% during the second quarter. Baird Financial Group Inc. now owns 13,089 shares of the biotechnology company’s stock valued at $1,488,000 after purchasing an additional 1,452 shares in the last quarter. 91.28% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on LGND. HC Wainwright raised their price objective on shares of Ligand Pharmaceuticals from $157.00 to $206.00 and gave the stock a “buy” rating in a report on Thursday, August 28th. Benchmark increased their price target on shares of Ligand Pharmaceuticals from $160.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, September 2nd. Wall Street Zen raised shares of Ligand Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Royal Bank Of Canada upped their price objective on Ligand Pharmaceuticals from $155.00 to $185.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. Finally, Oppenheimer lifted their target price on Ligand Pharmaceuticals from $190.00 to $250.00 and gave the company an “outperform” rating in a research report on Monday. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Ligand Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $186.50.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.